Vigil Neuroscience, Inc. (VIGL)
$
1.78
-0.13 (-7.30%)
Key metrics
Financial statements
Free cash flow per share
-1.2297
Market cap
89.1 Million
Price to sales ratio
0
Debt to equity
0.1807
Current ratio
2.9456
Income quality
0.6079
Average inventory
0
ROE
-0.9650
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Vigil Neuroscience, Inc. is a microglia-focused company dedicated to developing disease-modifying therapeutics for patients, caregivers, and families impacted by both rare and common neurodegenerative diseases. The diluted EPS is -$2.07 accounting for potential share dilution. The company reported an income before tax of -$84,256,000.00 showcasing its pre-tax profitability. The financial data pertains to the fiscal year 2024 while the operating expenses amount to $89,683,000.00 encompassing various operational costs incurred. Additionally, the net total of other income and expenses is $5,427,000.00 reflecting non-core financial activities. Vigil's lead product candidate is VGL101, a fully human monoclonal antibody (mAb) specifically designed to activate triggering receptor expressed on myeloid cells 2 (TREM2). Currently, it is in Phase I clinical trials for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as targeting cerebral adrenoleukodystrophy and Alzheimer's disease. Furthermore, the company is actively developing a small molecule TREM2 agonist suitable for oral delivery, aimed at treating common neurodegenerative diseases associated with microglial dysfunction. Founded in 2020, Vigil Neuroscience is headquartered in Cambridge, Massachusetts. As a small-cap player, Vigil Neuroscience operates with a market capitalization of $83,075,332.00 making it an enticing option for investors. The stock is affordable at $1.80 suitable for budget-conscious investors looking to enter the market. Despite its potential, the stock has a low average trading volume of 1,047,205.00 indicating lower market activity, which might reflect a cautious investor sentiment. Nevertheless, it is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Belonging to the Healthcare sector, Vigil drives innovation and growth, positioning itself as a noteworthy entity committed to advancing therapeutic options for neurodegenerative conditions.
What is Vigil Neuroscience, Inc. (VIGL)'s stock forecast?
Analysts predict Vigil Neuroscience, Inc. stock to fluctuate between $1.49 (low) and $6.06 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Vigil Neuroscience, Inc.'s market capitalization?
As of 2025-04-01, Vigil Neuroscience, Inc.'s market cap is $83,075,332, based on 46,671,535 outstanding shares.
How does Vigil Neuroscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Vigil Neuroscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Vigil Neuroscience, Inc. (VIGL) stock?
To buy Vigil Neuroscience, Inc. (VIGL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VIGL. Place an order (Market, Limit, etc.).
What is the best time to invest in Vigil Neuroscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Vigil Neuroscience, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.07 | Growth: -2.82%.
Where can I find Vigil Neuroscience, Inc.'s investor relations reports?
Visit https://www.vigilneuro.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Vigil Neuroscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Vigil Neuroscience, Inc. stock?
All-time high: $18.27 (2022-02-17) | All-time low: $1.49 (2024-12-30).
What are the key trends affecting Vigil Neuroscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
benzinga.com
On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer's disease.
globenewswire.com
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer's disease (AD) -
globenewswire.com
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 –
https://thefly.com
William Blair analyst Sarah Schram initiated coverage of Vigil Neuroscience with an Outperform rating.
prnewswire.com
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
globenewswire.com
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company.
globenewswire.com
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
globenewswire.com
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
prnewswire.com
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
See all news
